Hubungan Kadar Interleukin-10 dan Tuberkulosis Multi-Drug Resistant

Nurjanah Lihawa, Resti Yudhawati

= http://dx.doi.org/10.20473/jr.v1-I.2.2015.41-47
Abstract views = 176 times | views = 220 times

Abstract


Background: Prevalence of multi-drug resistant tuberculosis (MDR-TB) is increased by the time. In Indonesia, there were an  estimated 1.9% of new cases and 12% of previously treated cases. Protection against Mycobacterium tuberculosis is dependent on  Th1 cell CD4+ that produced pro-inflammatory cytokines such as IFN-γ and TNF-α. T cell regulators (Tregs) produced IL-10 as anti- inflammatory cytokine is against the function of those pro-inflammatory cytokines. It is believed that immune suppression is responsible  for MDR-TB. The previous study showed impaired Th1 responses and enhanced regulatory T-cell levels in circulatory blood of MDR- TB patients. The study of IL-10 represented anti-inflammation cytokine as immune suppression never been conducted in Indonesia.  Objective: To analyze relationship between level of interleukin-10 and Multi-drug resistant tuberculosis. Methods: The study was  conducted at the outpatient department of MDR-TB and DOTS of Dr. Soetomo hospital in Surabaya. Total sample was 38 of TB patients  that consist of 19 MDR-TB patients (secondary resistant) and 19 non-MDR TB patients as control. Results: In this study we found that  the median level of IL-10 as 5.7±3.3 pg/mL in the group of MDR-TB patients with minimum level was 1.3 pg/mL and maximum level  was 14.0 pg/mL while median level of IL-10 in non-MDR TB patients was 7.0±3.4 pg/mL with 3.2 pg/mL and 16.5 pg/mL, respectively.  To analyze correlation between time to first of having TB until became MDR-TB and level of IL-10 by using Pearson’s correlation, we  showed that no statistical correlation (p>0.05). According to statistical classification, we found that no statistical correlation between  level of IL-10 and the history of treatment in MDR-TB patients (p>0.05). Data showed that all the history of treatment classification  dominated by MDR-TB patients with the low level of IL-10. We also found that no statistical difference with the level of IL-10 in MDR- TB and non-MDR TB patients (p>0.05) although in descriptive state we found the level of IL-10 was higher in non-MDR TB patients.  And also there was no relationship between level of IL-10 and MDR-TB (p>0.05). It could be explained that the host factor was not  involved and in the other side we still not known the factor of agents, yet. The low level of IL-10 that was observed in this study could be  interfering by the strain of M.tb which not assessed in this study. Conclusion: In this study we found that level of IL-10 is not increase  in MDR-TB patients and there was no relationship between level of IL-10 and MDR-TB (p>0.05). 

Keywords


MDR-TB, Anti-inflammation cytokines, IL-10

Full Text:

PDF

References


WHO. Global Tuberculosis Report. ; 2012.

Yew WW, Chau CH. Drug-resistant tuberculosis in 1990s. Eur Respir J. 1995; 8: p. 1184-92.

Depkes R. Pedoman nasional pengendalian tuberkulosis Jakarta: Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan Kementrian Kesehatan Republik Indonesia; 2011.

Eum S, Jeon B, Min J, Kim S, Cho S, Park S, et al. Tumor Necrosis Factor-Alpha and Interleukin-10 in whole blood is associated with disease progression in pulmonary multidrug-resistant tuberculosis. Respiration. 2008; 76: p. 331-7.

Crevel RV, Ottenhoff T, Meer JVd. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15: p. 294-309.

Nachega J, Chaisson R. Tuberculosis drug resistance: a global threat. Clin Infect Dis. 2003; 36(Suppl 1): p. S24-30.

Thakker H, Shah J. Multi-drug resistant pulmonary tuberculosis. Ind J Tub. 1998; 45: p. 131-9.

Jurnal Respirasi (JR), Vol. 1. No. 2 Mei 2015: 41−47

Pinto L, Menzies D. Treatment of drug-resistant tuberkulosis. Infection and Drug Resistance. 2011; 4: p. 129-35.

Catagay T, Kiran B, Yurt S, Gulbaran Z, Kosar F, Catagay P. Level of tumor necrosis factor-alpha and IL-1alpha in newly diagnosed and multidrug resistant tuberculosis. Respirology. 2005; 10: p. 290-4.

Geffner L, Yokobori N, Basille J, Schierloh P, Balboa L. Patients with multi-drug resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multi-drug resistant tuberculosis M and Ra strains. Infect immun. 2009; 77 (11): p. 5025-34.

Skolimowska K, Rangaka M, Meintjes G, Pepper D, Seldon R, Matthews K, et al. Altered ratio of IFN-gamma/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV-tuberculosis Immune Reconstitution Inflammatory Syndrome. PLoS ONE. 2012; 7 (10): p. 1-7.

O’Leary S, O’Sullivan M, Keane J. IL-10 blocks Phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol. 2011; 45: p. 172-180.

Lee J, CH Song JL, Kim H, Park J, Paik T, Kim C, et al. The production of tumor necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30-kDa antigen Mycobacterium tuberculosis. Clin Exp Immunol. 2003; 132: p. 443-9.

Hopewell P. Tuberculosis and other Mycobacterial disease. In Mason RJ, Broaddus VC, Murray JF, Nadel JA. Murray and Nadel’s Textbook of Respiratory Medicine, 4th edition. Philadelphia: Elsevier Saunders; 2005. p. 984.

Hasan H. Tuberkulosis paru. In Wibisono MJ, Winariani , Hariadi S, editors. Buku Ajar Ilmu Penyakit Paru. 1st ed. Surabaya: Departemen Ilmu Penyakit Paru FK Unair-RSUD dr. Soetomo; 2010. p. 9.

Loeffler AM, editor. Drug-Resistant tuberculosis: a survival guide for clinicians Los Angeles: Francis J.Curry National Tuberculosis Centre, California Department of Public Health; 2008.

Pinheiro R, Dalcolmo M. Tuberculosis and multi-drug resistant tuberculosis: immunologic mechanisms and tools for controlling the disease. J Commun Inf Innov Health. 2008; 2 (1): p. 95-101.

PDPI. Tuberkulosis. Pedoman Diagnosis dan Penatalaksanaan di Indonesia Jakarta: Perhimpunan Dokter Paru Indonesia; 2011.

Raviglione MC, O’Brien RJ. Tuberculosis. In Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: the McGraw-Hill Co; 2008. p. 1006.

Khan AE, Kimerling ME. Chemotherapy of tuberculosis. In Schlossberg D, editor. Tuberculosis and Mycobacterium other than tuberculosis. 6th ed. Philadhelphia: the McGraw-Hill Co; 2006. p. 77.

Dheda K, Schwander S, Zhu B, Zyl-Smit Rv, Zhang Y. The Immunology of tuberculosis: From bench to bedside. Respirology. 2010; 15: p. 433-50.

Patel AM, Abrahams EW. Pulmonary tuberculosis. In Ratlegde, Stanford J, Grange JM, editors. The Biology of mycobacteria. London: Harcout Branch Jovanovick,Academic Press; 1989. p. 179-244.

Manabe YC, Dannenberg Jr AM. Pathophysiology: basic aspects. In Schlossberg D, editor. Tuberculosis and Non Tuberculosis Mycobacterial infection. 5th ed.: McGraw Hill; 2006. p. 18-51.

Raja A. Immunology of tuberculosis. Indian J Med Res. 2004; 120: p. 213-32.

Bezuidenhout J, Scheider JW. Pathology and pathogenesis of tuberculosis. In Schaaf HS, Zumla A, editors. Tuberculosis a comprehensive clinical reference.: Elsevier Saunders; 2009. p. 120.

Zainullah A. Immunopathogenesis of TB: ”how to apply in improving of TB treatment?” In Maranatha D, Soedarsono , Hasan H, editors. Simposium Nasional TB Up-date IV, Fighting TB: protect the vulnerable population from TB,TB/HIV,and MDR TB; 2007; Surabaya: Departemen Ilmu Penyakit Paru FK Unair-RSU dr. Soetomo. p. 51-61.

Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immun. 2011;: p. 1-17.

Schwander S, Ellner J. Human immune response to M. tuberculosis. In Davies P, Barnes P, Gordon S, editors. Clinical tuberculosis. 4th ed. London: Hodder Arnold an Hachette UK Company; 2008. p. 121.

Mertaniasih N, RJ S, Wahyunitisari M. Patogenesis tuberkulosis. In Mertaniasih N, Koendhori E, Kusumanigrum D, editors. Buku Ajar Tuberkulosis Diagnostik Mikrobiologis. 1st ed. Surabaya: LP3 UNAIR dan Pusat Penerbitan dan Percetakan UNAIR; 2013. p. 35-60.

Van Crevel R, Ottenhoff T, van der Meer J. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15: p. 294-309.

Abbas A, Lichtman A, Pillai S. Immunity to microbes. In Cellular and Molecular Immunology. 7th ed. Philadelphia: Elsevier Saunders; 2012. p. 350.

Abbas A, Lichtman A, Pillai S. Effector mechanisms of Cell- Mediated Immunity. In Cellular and Molecular Immunology. 7th ed. Philadelphia: Elsevier Saunders; 2012. p. 225.

Dachlan Y. Imunologi Tuberkulosis: sistem imun, pembentukan granuloma, dormansi, reaktivasi infeksi latent, MDR-tuberkulosisi. In The Problems of MDR TB from basic to clinic and community. Surabaya; 2012. p. 4-14.

Mitchison D. Drug resistant tuberculosis. Eur Respir J. 2005; 25: p. 376-9.

Snider DJR. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis. 1985; 132: p. 125-132.

Valway SE. Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. J Infect Dis. 1994; 170: p. 151-6.

Delves P, Martin S, Burton D, Roitt I. Fundamental of immunology: knowing when to make an immune response. In Roitt’s Essentials Immunology. 12th ed. United Kingdom: Wiley-Blackwell publishing; 2011. p. 4-6.

Cavalcanti Y, Brelaz M, Neves J, Ferras J, Pereira V. Role of TNF- Alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis. Pulmonary Medicine. 2012;: p. 1-10.

Williams A. Cytokines. In Immunology Mucosal and Body Surface Defences. United Kingdom: Wiley-Blackwell; 2012. p. 68-92.

Fiorentino D, MW B, Mosmann T. Two types of mouse T helper cell. Th2 clones secrete a factor that inhibits cytokines production by Th1 clones. J Exp Med. 1989; 170: p. 2081-95.

D’andrea A, Aste-Amezaga M, Valiante N. Interleukin-10 (IL- 10) inhibits human lymphocyte interferon gamma production by supressing Natural Killer Cell stimulatory factor/IL-12 synthesis in acessory cells. J Exp. Med. 1993; 178: p. 1041-8.

Couper K, Blount D, Riley E. IL-10: the master regulator of immunity to infection. J Immunol. 2008; 180: p. 5771-7.

Jacobs M, Bronw N, Allie N. Increase resistance to Mycobacterial infection in the absence of interleukin-10. Immunology. 2000; 100: p. 494-501.

Beamer G, Flaherty D, Assogba B, Stromberg P, Gonzales-Juarrero M, Waal-Malefyt Rd, et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol. 2008; 181: p. 5545-50.

Deveci F, Akbulut H, Turgut T. Changes in serum cytokine levels in active tuberculosis with treatment. Mediators of inflammation. 2005; 5: p. 256-62.

Zhang M, Gong J, Presky D. Expression of the IL-12 receptor B1 dan B2 subunits in human tuberculosis. J Immunol. 1999; 162: p. 2441-7.

Verbon A, Juffermans N, van Deventer S. Serum concentration of cytokines in patients with active tuberculosis and after treatment. Clin Exp Immunol. 1999; 115: p. 110-3.

Lago P, Boechat N, Migueis D, Almeida A, Lazzarini L, Zaldanha M, et al. Interleukin-10 and interferon-gamma pattern during tuberculosis treatment: possible association with recurrence. Int J Tuberc Lung Dis. 2012; 16 (5): p. 656-9.

biolegend.com. [Online]. [cited 2014 February 15. Available from: www.biolegend.com.

Dahlan M. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan Jakarta: Salemba Medika; 2010.

Yamasaki N, Ozasa K, Yamada, Otsuga, Shimouchi. Gender difference in delays to diagnosis and health care seeking behavior in rural area of Nepal. Int J Tuberc Lung Dis. 2001; 54 (1): p. 24-31.

Chiacchio T, Cassetti R, Butera O. Characterization of regulatory T cells identified as CD4 (+) CD25 (high) CD39(+) in patients with active tuberculosis. Clin Exp Immunol. 2009; 156: p. 463-70.

Sahiratmadja E, Alisjahbana B, de Boer T. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon signaling integrity correlate with tuberculosis disease activity and responsse to curative treatment. Infect Immun. 2007; 75 (2): p. 820-9.

Stead W. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residual of the primary infection or exogenous reinfection? Am Rev Respir Dis. 1967; 95: p. 729-45.

Van Rie A, Victor T, Richardson M. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistant patterns. Am J Respir Crit Care Med. 2005; 172: p. 636-42.

Flynn J, Chan J, Triebold K, Dalton D, Stewart T, Bloom B. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993; 178 (6): p. 2249-54.

McDyer J, Hackley M, Walsh T, Cook J, Seder R. Patients with multidrug-resistant tuberculosis with low CD4+ T cell counts have impaired Th1 responsses. J Immunol. 1997; 158 (1): p. 492-500.

Lee J, Song C, Kim C. Profiles of IFN-gamma and its regulatory cytokines (IL-12,IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis. Clin Exp Immunol. 2002; 128: p. 516-24.

Flynn J, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: p. 93-129.

Torres M, Herrera T, Villareal H, Rich E, Sada E. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in responsse to 30- kilodalton antigen of Mycobacterium tuberculosis. Infect Immun. 1998;: p. 176-80.

Eum S, Lee Y, Min J, Kwak H, Hong M, Kong J, et al. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with responsse to chemotherapy in patients with pulmonary multi-drug resistant tuberculosis. Respiration. 2010; 80: p. 275-84.

Pinheiro R, Oliveira Wd, Santos Gd, Silva Gd, Silva BdA, Teles R, et al. Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin Exp Immunol. 2012; 171: p. 210-9.

Lee J, Son H, Song C, Kim H, Park J, Paik T, et al. Dysregulated production of IFN-gamma, IL-12, and IL-10 by peripheral blood mononuclear cells from early active pulmonary and multi-drug resistant tuberculosis patients. J Bacteriol Virol. 2002; 32 (2): p. 211-9.

Shekar-Abi M, Miandehi N, Mansoori S, Fayri M, Alibahar M, Amirkhani A, et al. The study of Th1/Th2 cytokines profiles (IL- 10,IL-12,IL-4, and IFN-gamma) in PMBCs of patients with multidrug resistent tuberculosis and newly diagnosed drug responssive case. Tanaffos. 2004; 3 (10): p. 25-31.

Brudey K, Driscoll J, Rigouts L, Prodinger W, Gori A, Hajoj SA. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiology. 2006; 6: p. 23.

Rocha-Ramirez LM. Mycobacterium tuberculosis lipids regulate cytokines, TLR-2/4 and MHC class II expression in human macrophage. Tuberculosis. 2008; 88: p. 212-20.

Redford P, Murray P, O’Garra A. The role of IL-10 in immune regulation during M.tuberculosis infection. Mucosal Immunol. 2011 May; 4 (3): p. 261-70.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Jurnal Respirasi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Satats

Indexed by: